Gsa Capital Partners LLP Omeros Corp Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$3.04 - $4.23 $829 - $1,154	-273 Reduced 1.25%	21,482 $87,000
Q1 2024 May 03, 2024	BUY	$2.88 - $4.89 $62,654 - $106,381	21,755 New	21,755 $75,000
Q1 2023 May 12, 2023	BUY	$2.48 - $5.22 $124,178 - $261,375	50,072 New	50,072 $232,000
Q1 2022 May 11, 2022	SELL	$5.07 - $7.2 $229,711 - $326,217	-45,308 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.67 - $8.54 $104,679 - $157,665	-18,462 Reduced 28.95%	45,308 $291,000
Q3 2021 Nov 12, 2021	SELL	$13.4 - $16.3 $752,678 - $915,571	-56,170 Reduced 46.83%	63,770 $879,000
Q2 2021 Aug 05, 2021	BUY	$14.81 - $19.13 $1.78 Million - $2.29 Million	119,940 New	119,940 $1.78 Million
Q4 2020 Feb 03, 2021	SELL	$10.14 - $15.19 $153,783 - $230,371	-15,166 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$9.57 - $21.32 $145,138 - $323,339	15,166 New	15,166 $153,000
Q1 2020 May 12, 2020	SELL	$9.03 - $19.72 $213,613 - $466,496	-23,656 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$13.01 - $17.15 $140,716 - $185,494	10,816 Added 84.24%	23,656 $333,000
Q3 2019 Nov 12, 2019	BUY	$14.55 - $20.56 $186,822 - $263,990	12,840 New	12,840 $210,000

120

25.6M

228K

630K

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $647M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.